Identification of trimetazidine metabolites in human urine and plasma.
1. The objective was to use modern mass spectrometric techniques to update current information on the metabolism of trimetazidine in human subjects found by previous studies. 2. Urine and plasma samples were taken from four healthy human volunteers taking part in a larger kinetic study. Each subject received an oral dose of 80-mg trimetazidine daily for 4 days. 3. Identification and quantitation of trimetazidine and its metabolites in urine and plasma were achieved using modern liquid chromatography-mass spectrometric methods. 4. The major drug-related component observed in urine and plasma was unchanged trimetazidine. In addition to the parent drug, 10 metabolites were detected in urine in concentrations ranging from 0.008 (0.01% dose) to 1.094 micrograms.ml-1 (1.4% dose). Metabolic profiles following acute and chronic doses of trimetazidine were qualitatively similar.
Jackson
P J
PJ
Servier Research and Development, Ltd, Slough, UK.
Brownsill
R D
RD
Taylor
A R
AR
Resplandy
G
G
Walther
B
B
Schwietert
H R
HR
D000328:Adult; D001711:Biotransformation; D002853:Chromatography, Liquid; D005260:Female; D006801:Humans; D007202:Indicators and Reagents; D008297:Male; D013058:Mass Spectrometry; D014292:Trimetazidine / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D014665:Vasodilator Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D007202:Indicators and Reagents; D014665:Vasodilator Agents; D014292:Trimetazidine